Otsuka (OTCMKTS:OTSKY) Raised to “Hold” at Zacks Research

Otsuka (OTCMKTS:OTSKY) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Several other research analysts have also recently issued reports on the company. Morgan Stanley raised Otsuka to an “overweight” rating in a report on Friday, January 23rd. UBS Group raised Otsuka to a “hold” rating in a research note on Tuesday, January 27th. Finally, The Goldman Sachs Group lowered Otsuka from a “strong-buy” rating to a “strong sell” rating in a research report on Friday, February 27th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Otsuka Stock Up 2.9%

OTCMKTS OTSKY opened at $36.39 on Tuesday. Otsuka has a 12 month low of $21.64 and a 12 month high of $36.55. The company has a market capitalization of $39.09 billion and a P/E ratio of 15.82. The company’s 50 day simple moving average is $32.73 and its 200 day simple moving average is $29.65. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.17 and a quick ratio of 1.67.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.